Trial Profile
A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary)
- Indications Renal failure; Solid tumours
- Focus Adverse reactions
- 13 Aug 2018 Status changed from active, no longer recruiting to discontinued.
- 13 Aug 2018 Status changed from active, no longer recruiting to discontinued.
- 06 Jan 2016 Planned number of patients changed from 6 to 122 as per ClinicalTrials.gov record.